Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England

Fig. 1

Mean urinary keratan sulfate (uKS) over time (a) and box plot comparing uKS at pre-treatment baseline and at last follow-up among patients with both measures (N = 48; mean follow-up 4.9 years) (b). In the box plot, lines show medians and first and third quartiles; asterisks show means

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172